drugset / Trial / NCT06123884
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer
Timeline
- Start
- 2023-12-13
- Primary completion
- 2026-09
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT1308 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Bevacizumab Injection | Unknown | 15 mg/kg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Paclitaxel for Injection | Unknown | — | — |